Organisation paid for research Program year 2025 Source: CMS Open Payments

Aventiv Research INC-Dublin

Neither a doctor nor a teaching hospital

Research payments

$822,735

556 payments

Through program year 2025, Aventiv Research INC-Dublin is reported as receiving $822,735 in research payments, across 556 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$161,777	141
2024	Research	$90,442	112
2023	Research	$479,791	268
2022	Research	$90,726	35

Breakdown

Who paid Research payments · program years 2022–2025

Incyte Corporation $822,735 556 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies $264,060 21 payments
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis $86,825 32 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis $79,032 163 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis $63,726 33 payments
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $61,932 36 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis $55,480 77 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy And Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis $47,181 78 payments
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa $45,500 10 payments
An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib $37,654 9 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis $33,817 69 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.